<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<ns2:studies xmlns:ns2="http://webservice.caaers.cabig.nci.nih.gov">
    <ns2:study>
        <shortTitle>N0543, A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma</shortTitle>
        <longTitle>N0543, A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma</longTitle>
        <description>N0543, A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma</description>
        <phaseCode>Phase II Trial</phaseCode>
        <status>Active - Trial is open to accrual</status>
        <multiInstitutionIndicator>true</multiInstitutionIndicator>
        <adeersReporting>true</adeersReporting>
        <otherMeddra>MedDRA v9</otherMeddra>
        <ns2:aeTerminology>
            <ns2:ctcVersion>
                <name>3</name>
            </ns2:ctcVersion>
        </ns2:aeTerminology>
        <ns2:diseaseTerminology>
            <diseaseCodeTerm>CTEP</diseaseCodeTerm>
        </ns2:diseaseTerminology>
        <drugAdministrationTherapyType>true</drugAdministrationTherapyType>
        <deviceTherapyType>false</deviceTherapyType>
        <radiationTherapyType>false</radiationTherapyType>
        <surgeryTherapyType>false</surgeryTherapyType>
        <behavioralTherapyType>false</behavioralTherapyType>
        <biologicalTherapyType>false</biologicalTherapyType>
        <geneticTherapyType>false</geneticTherapyType>
        <dietarySupplementTherapyType>false</dietarySupplementTherapyType>
        <otherTherapyType>false</otherTherapyType>
        <reportTypeCaaersXML>true</reportTypeCaaersXML>
        <reportTypeAdeersPDF>true</reportTypeAdeersPDF>
        <reportTypeMedwatchPDF>true</reportTypeMedwatchPDF>
        <reportTypeDCPSAEForm>false</reportTypeDCPSAEForm>
        <reportTypeCIOMSForm>false</reportTypeCIOMSForm>
        <reportTypeCIOMSAEForm>false</reportTypeCIOMSAEForm>
        <fundingSponsor>
            <organizationAssignedIdentifier>
                <value>N0543</value>
            </organizationAssignedIdentifier>
            <ns2:studyFundingSponsor>
                <ns2:organization>
                    <name>Cancer Therapy Evaluation Program</name>
                    <nciInstituteCode>CTEP</nciInstituteCode>
                </ns2:organization>
            </ns2:studyFundingSponsor>
        </fundingSponsor>
        <coordinatingCenter>
            <organizationAssignedIdentifier>
                <value>N0543</value>
            </organizationAssignedIdentifier>
            <ns2:studyCoordinatingCenter>
                <ns2:organization>
                    <name>North Central Cancer Treatment Group</name>
                    <nciInstituteCode>NCCTG</nciInstituteCode>
                </ns2:organization>
            </ns2:studyCoordinatingCenter>
        </coordinatingCenter>
        <studyOrganizations>
            <ns2:studySite>
                <ns2:organization>
                    <name>Mayo Clinic Rochester</name>
                    <nciInstituteCode>MN026</nciInstituteCode>
                </ns2:organization>
                <studyPersonnels>
                    <ns2:studyPersonnel>
                        <roleCode>caaers_participant_cd</roleCode>
                        <startDate>2011-01-26</startDate>
                        <endDate>2011-03-26</endDate>
                        <ns2:researchStaff>
                            <firstName>Smoke</firstName>
                            <lastName>Tester1</lastName>
                            <nciIdentifier>SMOKE_RS_1</nciIdentifier>
                        </ns2:researchStaff>
                    </ns2:studyPersonnel>
                    <ns2:studyPersonnel>
                        <roleCode>caaers_participant_cd</roleCode>
                        <startDate>2010-02-26</startDate>
                        <endDate>2011-03-01</endDate>
                        <ns2:researchStaff>
                            <firstName>research</firstName>
                            <lastName>staff-ws</lastName>
                            <nciIdentifier>ws-rs1</nciIdentifier>
                        </ns2:researchStaff>
                    </ns2:studyPersonnel>
                    <ns2:studyPersonnel>
                        <roleCode>caaers_site_cd</roleCode>
                        <startDate>2010-02-26</startDate>
                        <endDate>2011-03-02</endDate>
                        <ns2:researchStaff>
                            <firstName>research</firstName>
                            <lastName>staff-ws</lastName>
                            <nciIdentifier>ws-rs1</nciIdentifier>
                        </ns2:researchStaff>
                    </ns2:studyPersonnel>
                </studyPersonnels>
            </ns2:studySite>
            <ns2:studySite>
                <ns2:organization>
                    <name>North Central Cancer Treatment Group</name>
                    <nciInstituteCode>NCCTG</nciInstituteCode>
                </ns2:organization>
                <startDate>2009-10-01</startDate>
                <endDate>2020-10-01</endDate>
            </ns2:studySite>
        </studyOrganizations>
        <identifiers/>
        <studyAgents>
            <ns2:studyAgent>
                <ns2:agent>
                    <name>Capecitabine (Xeloda)</name>
                </ns2:agent>
                <indType>NA_COMMERCIAL</indType>
            </ns2:studyAgent>
            <ns2:studyAgent>
                <ns2:agent>
                    <name>Irinotecan (CPT-11, Camptosar)</name>
                </ns2:agent>
                <indType>NA_COMMERCIAL</indType>
            </ns2:studyAgent>
            <ns2:studyAgent>
                <ns2:agent>
                    <name>OXALIplatin (Eloxatin)</name>
                </ns2:agent>
                <indType>NA_COMMERCIAL</indType>
            </ns2:studyAgent>
        </studyAgents>
        <ctepStudyDiseases>
            <ns2:ctepStudyDisease>
                <ns2:diseaseTerm>
                    <term>Adenocarcinoma - small intest.</term>
                </ns2:diseaseTerm>
                <leadDisease>true</leadDisease>
            </ns2:ctepStudyDisease>
            <ns2:ctepStudyDisease>
                <ns2:diseaseTerm>
                    <term>Hematopoietic malignancy, NOS</term>
                </ns2:diseaseTerm>
                <leadDisease>false</leadDisease>
            </ns2:ctepStudyDisease>
            <ns2:ctepStudyDisease>
                <ns2:diseaseTerm>
                    <term>Solid tumor, NOS</term>
                </ns2:diseaseTerm>
                <leadDisease>false</leadDisease>
            </ns2:ctepStudyDisease>
        </ctepStudyDiseases>
        <evaluationPeriods>
            <ns2:evaluationPeriod>
                <name>Baseline</name>
                <epochOrder>0</epochOrder>
            </ns2:evaluationPeriod>
            <ns2:evaluationPeriod>
                <name>Treatment</name>
                <epochOrder>1</epochOrder>
            </ns2:evaluationPeriod>
            <ns2:evaluationPeriod>
                <name>Post-treatment</name>
                <epochOrder>2</epochOrder>
            </ns2:evaluationPeriod>
        </evaluationPeriods>
    </ns2:study>
</ns2:studies>
